SCHEMBL17455970

SCHEMBL17455970

Cn1cc(S(=O)(=O)N2CCC(Oc3cc(F)ccc3-c3ccncc3)C2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM1 P11229 1/20 0.43
▸ IKBKB O14920 3/20 0.41
▸ CHUK O15111 2/20 0.41
▸ PSEN1 P49768 1/20 0.39
▸ PSEN2 P49810 1/20 0.39
▸ APH1B Q8WW43 1/20 0.39
▸ NCSTN Q92542 1/20 0.39
▸ APH1A Q96BI3 1/20 0.39
▸ PSENEN Q9NZ42 1/20 0.39
▸ TDO2 P48775 3/20 0.38
▸ GLRA3 O75311 2/20 0.38
▸ GLRB P48167 2/20 0.38
▸ MCHR1 Q99705 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HTR2C P28335 2/20 0.37
▸ KCNH2 Q12809 2/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ HTR1A P08908 1/20 0.36
▸ HTR7 P34969 1/20 0.36
▸ NR3C1 P04150 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17456023 0.94 CHRM1 (0.42) CHRM1IKBKBCHUKPSEN1PSEN2
SCHEMBL17455926 0.89 CHRM1 (0.38) CHRM1IKBKBCHUKPSEN1PSEN2
SCHEMBL17456035 0.83 CHRM1 (0.38) CHRM1PSEN1PSEN2APH1BNCSTN
SCHEMBL17455990 0.82 IKBKB (0.53) IKBKBCHUKTDO2CYP1A2
SCHEMBL17455945 0.82 CHRM1 (0.43) CHRM1IKBKBCHUKMCHR1HTR2C
SCHEMBL17455919 0.81 IKBKB (0.42) IKBKBCHUKTDO2CYP1A2
SCHEMBL17456027 0.79 CHRM1 (0.46) CHRM1
SCHEMBL21238823 0.78 TDO2 (0.42) IKBKBCHUKTDO2GLRA3GLRB
SCHEMBL17455929 0.77 CHRM1 (0.40) CHRM1IKBKBCHUKMCHR1HTR2C
SCHEMBL17455951 0.77 CHRM1 (0.41) CHRM1IKBKBCHUKMCHR1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 CHRM1 519/4885IKBKB 2723/4885CHUK 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback